5-y Follow-up Study of Patients with Neuroborreliosis
Overview
Affiliations
The objective of this follow-up study was to determine the long-term outcome of strictly classified cases of neuroborreliosis treated with antibiotics. A 1-y prospective population-based survey of Lyme borreliosis was conducted in southern Sweden between 1992 and 1993. A total of 349 identified cases with suspected neuroborreliosis were followed up 5 y later. Medical records were reviewed and all participants filled in a questionnaire. Of those patients classified with definite neuroborreliosis, 114/130 completed the follow-up, of whom 111 had completed the initial antibiotic treatment. Of the 114 patients followed up, 86 (75%) had recovered completely and 70 (61%) had recovered within 6 months. Residual neurological symptoms, such as facial palsy, concentration disorder, paresthesia and/or neuropathy, were reported by 28/114 patients. No significant differences between different antibiotic treatments were observed in terms of the occurrence of sequelae. To conclude, we found that 25% (95% confidence interval 17-33%) of the patients suffered from residual neurological symptoms 5 y post-treatment. However, the clinical outcome of treated neuroborreliosis is favorable as only 14/114 (12%) patients had sequelae that influenced their daily activities post-treatment. Early diagnosis and treatment would seem to be of great importance in order to avoid such sequelae.
Neuroborreliosis with encephalitis: a broad spectrum of clinical manifestations.
Hudasch D, Konen F, Mohn N, Grote-Levi L, Wurster U, Welte G BMC Infect Dis. 2025; 25(1):182.
PMID: 39920572 PMC: 11806785. DOI: 10.1186/s12879-025-10588-0.
Nymark A, Huniche L, Skarphedinsson S, Christensen H BMC Prim Care. 2024; 25(1):379.
PMID: 39443866 PMC: 11498949. DOI: 10.1186/s12875-024-02624-w.
Abdeljalil Z, Raphael A, Catherine C, Kevin B Eur J Pediatr. 2024; 183(12):5363-5370.
PMID: 39384650 DOI: 10.1007/s00431-024-05780-4.
Current and emerging approaches for eliminating and alleviating persistent Lyme disease symptoms.
Zafar K, Azuama O, Parveen N Front Microbiol. 2024; 15:1459202.
PMID: 39345262 PMC: 11427371. DOI: 10.3389/fmicb.2024.1459202.
Monaghan M, Norman S, Gierdalski M, Marques A, Bost J, DeBiasi R Pediatr Res. 2023; 95(1):3-4.
PMID: 37723215 DOI: 10.1038/s41390-023-02790-0.